Skip to main content

Table 1 CN ADNI subjects included in the longitudinal study

From: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition

  ADNI-1 ADNI-GO/2 CN stable ADNI-1 vs. ADNI-GO/2
  CN stable (n = 120) CN progressors (n = 35) p-value CN stable (n = 163) CN progressors (n = 8) p-value p-value
Progression to - 29 MCI - - 7 MCI -  
6 AD 1 AD
Age at baseline (years) 74.9 (72.0-78.5) 77.0 (73.0-79.2) 0.37 72.6 (69.4-77.1) 83.0 (80.4-84.8) 0.0001 0.0001
Gender (% male) 52.5% 57.1% 0.49 50.9% 75.0% 0.28 0.89
Education (years) 16.0 (14.0-18.0) 16.0 (13.0-18.0) 0.52 16.0 (15.0-18.5) 17.0 (13.8-18.5) 0.86 0.060
APOE ϵ4 presence 22.5% 31.4% 0.39 29.5% 12.5% 0.44 0.22
ADAS-Cog 9.33 (6.0-12.3) 10.8 (8.6-13.3) 0.047 9.0 (6.0-11) 15.0 (13.5-16.5) 0.0003 0.31
Memory summary score 0.94 (0.66-1.37) 0.71 (0.44-1.01) 0.006 0.94 (0.55-1.22) 0.22 (0.02-0.42) 0.0004 0.16
Executive summary score 0.66 (0.29-1.22) 0.40 (0.03-0.77) 0.039 0.82 (0.40-1.44) 0.23 [(−0.15)-0.47] 0.004 0.091
aHV1 812.0 (347.3-1244.5) 586.8 (94.5-1322.6)] 0.25 529.8 (9.0-1085.3) −226.1 [(−419.3)-(6.7)] 0.007 0.015
SPARE-AD −1.44 [(−2.15)-(−0.99)] −1.17 [(−1.74)-(−0.68)] 0.053 −1.32 [(−1.61)-(−1.07)] −0.90 [(−1.04)-(−0.30)] 0.029 0.019
HCI 5.3 (3.3-7.5) 6.0 (3.9-8.7) 0.20 5.5 (3.5-7.7) 7.2 (3.5-13.6) 0.051 0.29
PC-FDG-PET 1.38 (1.29-1.53) 1.29 (1.23-1.43) 0.022 1.45 (1.33-1.51) 1.31 (1.20-1.36) 0.014 0.54
1–42 (pg/ml) 222.0 (163.5-257.0) 210.0 (144.5-235.0) 0.25 207.7 (158.3-237.3) 147.8 (108.2-205.7) 0.083 0.065
T-tau (pg/ml) 60.0 (47.5-80.8) 71.5 (54.3-95.3) 0.13 56.3 (45.6-81.0) 111.5 (93.7-123.4) 0.032 0.53
P-tau181 (pg/ml) 20.0 (16.0-27.5) 22.0 (17.0-31.5) 0.36 30.0 (21.9-43.1) 35.6 (31.0-44.0) 0.25 <0.0001
  1. aHV = adjusted hippocampal volume.
  2. 1Adjusted for intracranial volume.
  3. Median (1st quartile-3rd quartile).